| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3675d00f905863ab0ddd24d2bb60daf5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F13-00017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04 |
| filingDate |
2012-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b25560a0dba5e380288b7ebeb52a92d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a42c90cd43f0a2a602be23d5ba4d7fe8 |
| publicationDate |
2016-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-616500-A |
| titleOfInvention |
Treatment of disease with poly-n-acetyglucosamine nanofibers |
| abstract |
Discloses the use of a composition comprising shortened fibres of poly-β-1→4-N-acetylglucosamine (“sNAG nanofibers”) in the manufacture of a medicament for treating a viral infection or a viral disease in a human subject having a viral infection or a viral disease, wherein the treating comprises topically administering the composition comprising the sNAG nanofibres to the human subject, and wherein (i) more than 50% of the sNAG nanofibres are between about 1 to 15 μm in length, or (ii) the average length of the sNAG nanofibres is less than 15 μm. |
| priorityDate |
2011-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |